Supplementary Materials

Supplementary Material for:

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Boris Julg, Lawrence J. Tartaglia, Brandon F. Keele, Kshitij Wagh, Amarendra Pegu, Devin Sok, Peter Abbink, Stephen D. Schmidt, Keyun Wang, Xuejun Chen, M. Gordon Joyce, Ivelin S. Georgiev, Misook Choe, Peter D. Kwong, Nicole A. Doria-Rose, Khoa Le, Mark K. Louder, Robert T. Bailer, Penny L. Moore, Bette Korber, Michael S. Seaman, Salim S. Abdool Karim, Lynn Morris, Richard A. Koup, John R. Mascola, Dennis R. Burton, Dan H. Barouch*

*Corresponding author. Email: dbarouch{at}bidmc.harvard.edu

Published 6 September 2017, Sci. Transl. Med. 9, eaal1321 (2017)
DOI: 10.1126/scitranslmed.aal1321

This PDF file includes:

  • Fig. S1. Highlighter amino acid sequence alignment of env derived from the SHIV-325c stock and the parental HIV-1 env.
  • Fig. S2. Serum concentration of CAP256-VRC26.25-LS and CAP256-VRC26.25 in naïve, uninfected rhesus macaques.
  • Table S1. IC80 (μg/ml) values of PGDM1400 and CAP256-VRC26.25 against SHIV-325c and a multiclade panel of 208 HIV-1 pseudoviruses.
  • Table S2. Neutralization of JR-CSF alanine variants by PGDM1400 or PG9.
  • Table S3. Primary data for Fig. 1 and fig. S2.

[Download PDF]